Amedeo's Top 20

Amedeo Smart

Independent Medical Education

17 July 2023

Multidisciplinary Journal Club

  1. Garvey WT, Frias JP, Jastreboff AM, le Roux CW, et al.
    Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Lancet 2023.

  1. Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, et al.
    Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet 2023.

  2. Wu P, Green M, Myers JE.
    Hypertensive disorders of pregnancy.
    BMJ 2023;381:e071653.

  3. Rosenstock J, Frias J, Jastreboff AM, Du Y, et al.
    Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
    Lancet 2023.

  4. Jones CMP, Day RO, Koes BW, Latimer J, et al.
    Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial.
    Lancet 2023.

  1. de Vries S, Krul I, Schaapveld M, Janus CMP, et al.
    Risk of male breast cancer after Hodgkin lymphoma.
    Blood 2023.

  2. Huber S, Baer C, Hutter S, Dicker F, et al.
    AML classification in the year 2023: How to avoid a Babylonian confusion of languages.
    Leukemia 2023;37:1413-1420.

  3. Aroda VR, Aberle J, Bardtrum L, Christiansen E, et al.
    Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.
    Lancet 2023.

  4. Kurian AW, Abrahamse P, Furgal A, Ward KC, et al.
    Germline Genetic Testing After Cancer Diagnosis.
    JAMA 2023;330:43-51.

  5. Chow R, Hasan S, Choi JI, Fox J, et al.
    Effect of Treatment Interruptions on Overall Survival in Patients with Triple Negative Breast Cancer.
    J Natl Cancer Inst 2023.

  1. Pourhadi N, Morch LS, Holm EA, Torp-Pedersen C, et al.
    Menopausal hormone therapy and dementia: nationwide, nested case-control study.
    BMJ 2023;381:e072770.

  2. Noel JE, Sinclair CF.
    Radiofrequency Ablation for Benign Thyroid Nodules.
    J Clin Endocrinol Metab 2023.

  3. Paik S, Tang G, Shak S, Kim C, et al.
    Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer.
    J Clin Oncol 2023;41:3565-3575.

  4. Kroupa R, Pavlik T, Konecny S, Packova B, et al.
    The association between duration of and indications for proton pump inhibitor use and risk of gastric polyps.
    Eur J Gastroenterol Hepatol 2023;35:829-835.

  5. Ploumen RAW, Claassens EL, Kooreman LFS, Keymeulen KBMI, et al.
    Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis.
    Breast Cancer Res Treat 2023.

  1. Wu Q, Zhou J, Huang J, Deng X, et al.
    Total neoadjuvant therapy versus chemoradiotherapy for locally advanced rectal cancer: Bayesian network meta-analysis.
    Br J Surg 2023;110:784-796.

  2. Dicpinigaitis AJ, Dick-Godfrey R, Gellerson O, Shapiro SD, et al.
    Real-World Outcomes of Endovascular Thrombectomy for Basilar Artery Occlusion: Results of the BArONIS Study.
    Ann Neurol 2023.

  3. Jackson EB, Chia SKL.
    Sequencing of Endocrine and Targeted Therapies in Hormone-Sensitive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
    J Clin Oncol 2023.

  4. Herr DJ, Elliott DA, Duchesne G, Stensland KD, et al.
    Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system.
    Cancer 2023.

  5. Stevens A, Meier J, Bhat A, Knight SJ, et al.
    Reassessing surgical guidelines for papillary thyroid cancer impact on survival: Expanding indications for lobectomy.
    Surgery 2023.


more..

Privacy Policy